52.14
4.16%
2.08
시간 외 거래:
52.55
0.41
+0.79%
왜 Corcept Therapeutics Inc (CORT) 주가가 하락하고 있습니까?
2024-08-02 거래 세션 동안 Corcept Therapeutics Inc(CORT) 주식이 6.96% 하락한 것을 확인했습니다. 이는 정상적인 변동성이나 다양한 내부 및 외부 요인에 의한 것일 수 있지만, 상황을 적극적으로 모니터링하고 있으며 최대한 빨리 적시에 업데이트를 제공하도록 하겠습니다!
2024-01-02:
Corcept Therapeutics Inc (CORT) stock dropped by 25.62% due to a patent infringement lawsuit outcome against Teva Pharmaceuticals (TEVA), negatively impacting Corcept's shares.
- Lawsuit Outcome and Generic Competition: The United States district court ruled against Corcept Therapeutics in its lawsuit related to its drug Korlym, which treats Cushing's syndrome. Teva Pharmaceuticals prevailed in the lawsuit as Corcept failed to demonstrate the likelihood of patent infringement.
- Impact on Korlym Sales and Stock Price: Korlym has been Corcept's primary revenue source, contributing $346.9 million in sales during the first nine months of 2023. The court's decision is expected to allow generic competition, potentially reducing Korlym's sales in 2024 and beyond.
- Stock Price Reaction: The negative outcome of the lawsuit had an immediate impact on Corcept's stock price, leading to a significant decline. While the stock had previously experienced a 61% rally over the past year, concerns about future sales and competition for Korlym contributed to the stock's drop.
자본화:
|
볼륨(24시간):